Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
HemoSonics LLC
| Company | HemoSonics LLC |
|---|---|
| Instrument name | Quantra Hemostasis Analyzer |
| Contact | Chris Gillespie |
| City State | Durham, NC |
| Phone | 919-886-9674 |
| Website | |
| First year sold | 2019 |
| List price/Model type | —/portable, benchtop |
| Dimensions (H × W × D)/Weight/Instrument footprint | 19 × 14 × 12 in./36 lbs./1 sq. ft. |
| No. of units in clinical use in U.S./Outside U.S. | >150/>150 (Europe, Japan, Hong Kong) |
| Composition of installs: Hospital lab/Reference lab/Other | 35%/0/65% (point of care [operating room, ICU, stat lab, more]) |
| Targeted daily, monthly, annual test volume | daily: 15–20; monthly: 1–200; annual: 1, 200–2, 400 |
| Operational type | random access, continuous random access |
| Country where analyzer designed/Manufactured | U.S./U.S. |
| Company manufactures instrument | yes |
| FDA-approved clotting-based tests | QPlus cartridge: clot time, clot time with heparinase, clot time ratio, clot stiffness, more; QStat cartridge: clot time, clot stability to lysis, clot stiffness, platelet contribution to clot stiffness, more |
| FDA-approved chromogenic tests | — |
| FDA-approved immunologic tests | — |
| Other FDA-approved tests | — |
| User-defined tests in clinical use | — |
| Tests in development or awaiting FDA 510(k) clearance | — |
| Methodologies supported | clot detection, sonic estimation of elasticity via resonance (SEER) sonorheometry |
| Number of different measured assays onboard simultaneously | QPlus cartridge: 6; QStat cartridge: 5 |
| Number of different assays programmed and calib. at one time | no calibration required |
| No. of user-definable (open) channels/No. active simultaneously | — |
| Factor assays require manual manipulation or dilutions | — |
| Test throughput per hour/Assay run time | 5–6 (25–36 tests in throughput)/7–60 min. (avg. 12.5 min.) |
| Design of sample-handling system | sealed room-temperature-stable cartridges accept a standard 3.2% citrate blue top tube, manually affixed to cartridge |
| Operates on whole blood or spun plasma | whole blood |
| Reagent type | self-contained single-use cartridges (lyophilized [reconstituted manually]) |
| Reagent barcode-reading capability | yes, for all tests |
| No. of reagent containers held onboard/Reagents ready to use | 1 cartridge/yes |
| Reagent lot tracking/Reagent inventory/Reagents refrigerated onboard | yes/no/no (20°–25°C) |
| Reagents, consumables loaded without interrupting testing | no |
| Instrument uses proprietary or third-party reagents | proprietary reagents |
| Maximum time same lot number of reagents can be used | — |
| Walkaway capability/Walkaway duration | yes/~12.5 min. or 1 specimen or 5–6 tests |
| Min.–max. specimen volume that can be aspirated at one time | — |
| Min. sample volume required for PT/PTT/Factor VIII activity | — |
| Types of disposables used | single use cartridges, weekly cleaning cartridge, QC level 1 and 2 |
| Primary tube sampling supported/Pierces caps on primary tubes | yes/yes |
| Accommodates most standard tube sizes/Nonstandard sizes | yes/— |
| Sample barcode-reading capability/Autodiscrimination | yes/— |
| Auto tracks product volume/Measures number of tests remaining | — |
| Short sample detection | — |
| Clot detection as preanalytical variable in plasma sample | — |
| Auto detects adequate reagents for aspiration or analysis | — |
| Detection or quantitation for hemolysis, turbidity, icterus, lipemia | no |
| Dilutes patient samples onboard | no |
| Automatic rerun capability/Auto reflex testing capability | no/no |
| Lag time during which hypercoagulable sample not detected | no |
| User can adjust reagent volumes/Sample volumes | no/no |
| User can adjust No. of reagents/Sources of reagents | — |
| User can adjust incubation times/Reading times | no/variable |
| Autocalibration/Calibrants stored onboard | — |
| Multipoint calibration supported/Recommended frequency | no calibration required |
| • PT alone | — |
| • PT, PTT | — |
| • Fibrinogen | fibrinogen contribution to clot stiffness: ~12.5 min./— |
| • Factor VIII activity assay | — |
| • D-dimer | — |
| Time delay from ordering stat to aspiration of sample | none |
| How labs get LOINC codes for results | email query, included in Quantra System implementation guide, addressed during training |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Information that can be barcode-scanned on instrument | operator identifier, specimen identifier, reagent lot No., lot specific QC target ranges, container ID |
| Compatible with laboratory automation systems | no |
| Data-management capability/LIS or EHR systems interfaced | onboard/yes |
| Interface supplied by instrument vendor | yes |
| Results transferred to LIS as soon as test time complete | yes |
| Bidirectional interface capability | yes (broadcast download and host query) |
| Remote servicing provided/UPS backup power supply | no/yes |
| Instrument connections to transfer information | directly to LIS; commercial middleware (RALS, Telcor, UniPOC, Cobas Infinity, DI Data Innovations) |
| Interface standards supported | LIS: compliant to CLSI LIS02-A2; POC testing middleware: compliant to CLSI POCT01-A2 |
| Information transferred to data-management software | device unique identifier, operator ID, patient ID, result, QC identifier, date and time of assay start, container ID, more |
| Avg. time for basic user training | up to 14 days (at customer site) |
| Approximate scheduled maintenance time | weekly: 3 minutes; monthly: 12 minutes |
| Maintenance records kept onboard | yes |
| Warranty with purchase/Annual service contract cost (24/7) | yes/— (cost dependent on contract) |
| Distinguishing features (supplied by company) | proprietary ultrasound technology directly measures the physical properties of a developing clot; wide range of clinical indications with simplified interpretation allows for better communication; novel technology allows for parameters not available in other systems, e.g. platelet contribution to clot |